TheraRadar
← Back
Data updated: Nov 8, 2026

Aurobindo Pharma

Generics
CardiovascularNeurologyInfectious Disease

Aurobindo Pharma is a generic drug manufacturer focused on Cardiovascular, Neurology, Infectious Disease. Key products include LAMIVUDINE; ZIDOVUDINE.

1968
Since
451
Drugs
-
Trials
2
New Drugs (2yr)
Modality:
7 Small Molecules

Aurobindo Pharma's Recent FDA Approvals

Aurobindo Pharma secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

DULOXETINE HYDROCHLORIDE NDA
2026-02-27
duloxetine hydrochloride
FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

Aurobindo Pharma's Therapeutic Areas

Aurobindo Pharma's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 7 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 36%
44 drugs
Neurology 21%
26 drugs
Infectious Disease 20%
24 drugs
Dermatology 13%
15 drugs Phase 3: 1
Immunology 10%
12 drugs

Aurobindo Pharma Pipeline Snapshot

Aurobindo Pharma has 1 active clinical program from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 0 Phase 1.

1
Phase 3
0
Phase 2
0
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • PRASUGREL leads revenue
  • • 5 key drugs tracked

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling